Immune checkpoint therapy—current perspectives and future directions
P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui… - Cell, 2023 - cell.com
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …
patients and conferred durable clinical benefits, including cure in a subset of patients …
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
TK Kim, EN Vandsemb, RS Herbst… - Nature Reviews Drug …, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
AX Zhu, AR Abbas, MR de Galarreta, Y Guan, S Lu… - Nature medicine, 2022 - nature.com
Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …
endothelial growth factor (VEGF)) combination therapy has become the new standard of …
[HTML][HTML] Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …
Targeting the gut and tumor microbiota in cancer
EM Park, M Chelvanambi, N Bhutiani, G Kroemer… - Nature medicine, 2022 - nature.com
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …
shaping cancer immunosurveillance and response to immunotherapy. Our understanding of …
Resistance mechanisms to anti-PD cancer immunotherapy
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
Q Huang, X Wu, Z Wang, X Chen, L Wang, Y Lu… - Cell, 2022 - cell.com
Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L) 1 blockade in patients with non-small cell lung cancer
Immunotherapy is used to treat almost all patients with advanced non-small cell lung cancer
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
(NSCLC); however, identifying robust predictive biomarkers remains challenging. Here we …
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer
Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …